Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J Mult Scler. 2013 Sep 10. PMID: 24022270. Abstract CommentRecommendBookmarkWatch